Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SNCA | P37840 | 1/20 | 0.57 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATP4A | P20648 | 3/20 | 0.51 |
| ▸ | ATP4B | P51164 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18726375 | 0.96 | APP (0.71) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL14583703 | 0.92 | APP (0.71) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL3724320 | 0.91 | ATP4A (0.60) | APPMAPTSULT1A1GLAGAA | |
| SCHEMBL5053235 | 0.91 | ATP4A (0.60) | APPMAPTSULT1A1GLAGAA | |
| SCHEMBL24133654 | 0.90 | APP (0.65) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL25839107 | 0.87 | APP (0.74) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL8555881 | 0.86 | ATP4A (0.53) | APPSULT1A1MEN1GLAGAA | |
| SCHEMBL12808066 | 0.86 | APP (0.70) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL13453288 | 0.86 | APP (0.70) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL5946646 | 0.85 | ATP4A (0.54) | APPSULT1A1MEN1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | APP 243/4885MAPT 160/4885SNCA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.